Journal of Microencapsulation Impact Factor & Information

Publisher: Informa Healthcare

Journal description

The Journal of Microencapsulation is a well-established journal devoted to the preparation, properties and uses of individually encapsulated small particles. Its scope extends beyond microcapsules to all other small particulate systems which involve preparative manipulation. These forms find a wide variety of medical, biological, industrial and research applications. The journal covers the chemistry of encapsulation materials; the physics of release through the capsule wall; the techniques of preparation; content and storage; and the many uses to which microcapsules are put. Also found in every issue of the journal is an extensive information and reference section comprising patent briefing and literature alerts listings.

Current impact factor: 1.59

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 1.585
2013 Impact Factor 1.878
2012 Impact Factor 1.571
2011 Impact Factor 1.553
2010 Impact Factor 1.515
2009 Impact Factor 1.89
2008 Impact Factor 1.314
2007 Impact Factor 1.168
2006 Impact Factor 0.805
2005 Impact Factor 1.37
2004 Impact Factor 1.492
2003 Impact Factor 0.915
2002 Impact Factor 1.024
2001 Impact Factor 0.966
2000 Impact Factor 1.076
1999 Impact Factor 0.991
1998 Impact Factor 0.841
1997 Impact Factor 0.775
1996 Impact Factor 0.514
1995 Impact Factor 0.783
1994 Impact Factor 0.442
1992 Impact Factor 0.43

Impact factor over time

Impact factor

Additional details

5-year impact 1.75
Cited half-life 9.30
Immediacy index 0.21
Eigenfactor 0.00
Article influence 0.36
Website Journal of Microencapsulation website
Other titles Journal of microencapsulation (Online)
ISSN 0265-2048
OCLC 41407365
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • Non-commercial
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification
    ​ yellow

Publications in this journal

  • Neslihan Üstündağ Okur · Aysu Yurdasiper · Evren Gündoğdu · Evren Homan Gökçe
    [Show abstract] [Hide abstract]
    ABSTRACT: Nebivolol (NB)-loaded solid lipid nanoparticles (SLNs) were prepared and modified with chitosan oligosaccharide lactate (COL) and polyethylene glycol (PEG) stearate for improvement of its oral bioavailability. Compritol, poloxamer and lecithin were used for the preparation of SLNs by homogenisation method. After in vitro characterisation effect of lipase, pepsin, or pancreatin on degradation and release rate were investigated. Cytotoxicity and permeation were studied on Caco-2 cells. As COL concentration increased in SLNs, size and zeta potential increased. PEG concentration was reversely proportional to particle size with no change in zeta potential. Encapsulation efficiencies (EEs) were determined as 84–98%. DSC confirmed solubilisation of NB in lipid matrix. A sustained release with no burst effect was determined. The presence of enzymes affected the release. SLNs did not reveal cytotoxicity and highest permeability was obtained with PEG modification. PEG-modified SLNs could be offered as a promising strategy for oral delivery of NB.
    Journal of Microencapsulation 10/2015; DOI:10.3109/02652048.2015.1094532
  • [Show abstract] [Hide abstract]
    ABSTRACT: SN-38 is a highly effective drug against many cancers. The development of an optimal delivery system for SN-38 is extremely challenging due to its low solubility and labile lactone ring. Herein, SN-38 encapsulated in poly(d,l-lactide-co-glycolide) nanoparticles (NPs) is introduced to enhance its solubility, stability and cellular uptake. SN-38-loaded NPs prepared by spontaneous emulsification solvent diffusion (SESD) method had an average diameter of 310 nm, a zeta potential of -9.69 mV and a loading efficiency of 71%. They were able to protect the active lactone ring of SN-38 against inactivation under physiological condition. A colorectal adenocarcinoma cell line (COLO-205) was used to assess the NPs effects on cytotoxicity and cellular uptake. Result showed a significant decreased cell proliferation and cell apoptosis. These results suggest that these SN-38-loaded NPs can be an effective delivery system for the treatment of colon cancer and potentially for other types of cancers.
    Journal of Microencapsulation 09/2015; DOI:10.3109/02652048.2015.1081416
  • Journal of Microencapsulation 08/2015; DOI:10.3109/02652048.2015.1073384
  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins are drugs traditionally used to lower cholesterol levels in blood. At concentrations 100- to 500-fold higher than those needed for reaching cholesterol lowering activity, they have anti-tumour activity. This anti-tumour activity is based on statins pleiotropic effects derived from their ability to inhibit the mevalonate synthesis and include anti-proliferative, pro-apoptotic, anti-angiogenic, anti-inflammatory, anti-metastatic actions and modulatory effects on intra-tumour oxidative stress. Thus, in this review, we summarise the possible pleiotropic actions of statins involved in tumour growth inhibition. Since the administration of these high doses of statins is accompanied by severe side effects, targeted delivery of statins seems to be the appropriate strategy for efficient application of statins in oncology. Therefore, we also present an overview of the current status of targeted delivery systems for statins with possible utilisation in oncology.
    Journal of Microencapsulation 08/2015; DOI:10.3109/02652048.2015.1073383
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mercury is one of the most toxic pollutants, with high capacity of accumulation in living organism, causing important human health problems. Therefore, the mercury removal from water is an important research goal. In a previous work, an extractant agent [di(2-ethylhexyl)phosphoric acid] was microencapsulated in poly(styrene-co-divinylbenzene) by means of suspension polymerisation using toluene as diluent. In this study, this recipe has been modified changing the toluene by heptane and extended to four additional extractants (trioctylamine, trioctylmethylammonium chloride [TOMAC], tributyl phosphate and trioctylphosphine oxide). The polluting potential of the waste liquid from the process was measured by total organic carbon and chemical oxygen demand analyses. The morphology, particle size and distribution were studied by scanning electron microscopy and low angle laser light scattering. The amount of extractant agent into the microcapsules and the microencapsulation efficiency were determined by thermogravimetric analysis and the mercury removal capacity by equilibrium studies. Microcapsules containing TOMAC demonstrated to be the best material for the mercury removal and retention.
    Journal of Microencapsulation 08/2015; DOI:10.3109/02652048.2015.1073385
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of our study was to improve the bioavailability of acyclovir (ACV) by delivery of mucoadhesive nanoparticles (NPs) and controlled delivery of drug at its absorption window. Central composite design was used by which the effects of independent variables (gelatin and Pluronic F-68) on various responses such as particle size, polydispersity index, entrapment efficiency, loading efficiency, drug release and mucoadhesive strength were studied. The optimised formulation was evaluated for morphology, stability, pharmacokinetic and gastrointestinal tracking. The optimised NPs were found to be nearly spherical. Changes in characteristics of NPs were not significant after six months of accelerated stability studies. In vivo mucoadhesion study showed significant retention of mucoadhesive NPs in upper gastro-intestinal tract for more than 12 h. Pharmacokinetic study in rats revealed that mucoadhesive NPs could maintain relatively steady plasma concentration of ACV for more than 10 h. The AUC0–∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).
    Journal of Microencapsulation 08/2015; 32(6). DOI:10.3109/02652048.2015.1010457
  • [Show abstract] [Hide abstract]
    ABSTRACT: We prepared a magnetic chitosan-cis-aconitic anhydride-doxorubicin nanocomposite, denoted by MCS-CAA-DOX. Chitosan (CS) was linked to magnetic nanoparticles (Fe3O4) to decrease cytotoxicity of the composite and provided a large number of reactive sites for coupling of drug molecules. DOX was attached to the magnetic chitosan (MCS) via a pH-sensitive linker, cis-aconitic anhydride, which hydrolyses in the acidic lysosomal environment to allow pH-responsive release of DOX. The prepared nanocomposites were within 15 nm and had good superparamagnetic properties. The loading rate of DOX was up to 83%. It was found that nearly 88% DOX was released within 60 h at pH 5.0, compared with only 29% at pH 7.4.
    Journal of Microencapsulation 08/2015; 32(6). DOI:10.3109/02652048.2015.1065918
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Ciprofloxacin (CIP) was effective in treating bacterial keratitis. The purpose of this study was to prepare an effective prolonged-release of CIP by both temperature and pH-triggered in situ nanogels for the treatment of keratitis. Materials and methods: Poly(N-isopropylacrylamide-methacrylicacide-vinylpyrrolidone) [P (NIPAAm-MAA-VP)] nanoparticles was synthesised and used for preparation of CIP-loaded nanogels. Antimicrobial and in vivo animal studies of the CIP-loaded nanoformulation were performed. Results: Nanoformulation with a mean particle size between 10 and 50 nm and higher than 95% encapsulation efficiency was obtained. Ciprofloxacin released from the nanoparticles showed an enhanced antibacterial effect as determined by minimal inhibitory concentrations. In vivo studies demonstrated reasonable efficacy in severe keratitis using the developed nanoformulation. Conclusions: Nanoformulation had acceptable efficacy in treating bacterial keratitis in an animal model. Therefore, the developed system has the potential to be used in localised application for the treatment of keratitis.
    Journal of Microencapsulation 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this research was to evaluate the potential of water-in-oil-in-water (w/o/w) and solid-in-oil-in-water (s/o/w) emulsification techniques to prepare the altered collagen type II peptide AP268-270 (ACTP)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres to make ACTP more convenient as an rheumatoid arthritis treatment. Microspheres produced by the s/o/w method had higher drug encapsulation efficiency (69.7–79.8%) than those prepared by the w/o/w method (21.8–39.3%). In vitro drug release was influenced by the microencapsulation technique, molecular weight, and composition of the polymer. After intramuscular injection of the optimal formulation to Lewis rats, the concentration of ACTP peptide in serum reached its maximum level on day 3 and then remained nearly stable for approximately 4 weeks. In a collagen-induced arthritis rat model, a single intramuscular injection of ACTP-loaded PLGA microspheres had comparable efficacy to the intravenous injection of ACTP peptide solution once every other day.
    Journal of Microencapsulation 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Effective clinical utilisation of non-steroidal anti-inflammatory drugs, such as diclofenac sodium (DS) is significantly limited by their ulcerogenic potential and poor bioavailability after oral administration. The objective of this work was to develop reconstitutable pediatric suspensions of DS-loaded microspheres prepared with an acrylic polymer (Eudragit RS) for improved pediatric delivery of DS. The microspheres were prepared by the water-in-oil-in-water or solid-in-oil-in-water emulsion techniques. Enviromental scanning electron microscopy observations clearly showed that microspheres have spherical shape. The drug entrapment efficiency of these microspheres was found 47.96 ± 0.79% to 88.57 ± 0.59% and their average particle sizes were 23.94–60.78 µm, which are within the desired range for the development of suspension formulation. The in vitro dissolution indicated prolonged sustained release of DS over 8 h. The results of preliminary characterisation studies of suspensions show that a liquid pharmaceutical preparation for oral administration capable of providing a sustained release of DS was successfully obtained.
    Journal of Microencapsulation 07/2015; 32(4). DOI:10.3109/02652048.2015.1017616
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spherical microparticles for encapsulation of drugs for the treatment of diseases, with a diameter ranging between 2 and 4 µm, were obtained by double crosslinking (ionic and covalent) of chitosan and poly(vinyl alcohol) blend in a water-in-oil emulsion. Microparticles characterisation was carried out in terms of structural, morphological and swelling properties in aqueous media. The presence of chitosan in particles composition confers them a pH-sensitive character. Toxicity and hemocompatibility tests prove the biocompatible character of microparticles. The pilocarpine loading capacity is high as well as the release efficiency which increases up to 72 and 82% after 6 h. The obtained results recommend the microparticles as sustained release drug carriers for the treatment of eye diseases.
    Journal of Microencapsulation 05/2015; 32(4). DOI:10.3109/02652048.2015.1035682
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Scaffold if suitably modified could be used as a drug delivery system. Objective: To develop chitosan scaffold as a delivery system for delivering curcumin in wound-healing application. Materials and methods: Chitosan–curcumin microcomplex particles were prepared, and the effect of drug–polymer ratio (DPR) and homogenisation speed (HS) was studied using a two-level full-factorial design. Chitosan scaffold was prepared and incorporated with curcumin microcomplexes to obtain a chitosan scaffold-containing chitosan–curcumin microcomplex (CS-CCM). Antimicrobial property of the CS-CCM against Escherichia coli was studied. The cytotoxicity of CS-CCM was studied by assessing the cell viability by MTT assay. Results and discussion: DPR had a significant effect (p ≤ 0.05) on the drug content. CS-CCM was able to inhibit the growth of E. coli considerably. The MTT results showed that CS-CCM is non-cytotoxic and supports cell proliferation. Conclusion: CS-CCM due to its biocompatibility and antimicrobial property could be further evaluated for potential application in wound healing.
    Journal of Microencapsulation 04/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract This study evaluated the feasibility of mizolastine-loaded microparticles as therapy for atopic dermatitis. Microparticles have been researched for decades as a controlled-release drug delivery system, but seldom been used as treatment for skin disease. In this research, we induced dermatitis in BALB/c mice model by repeated topical application of dinitrofluorobenzene and compared the mizolastine microparticles injection and daily mizolastine injection treatment. The results showed that the mizolastine microparticles treatments significantly inhibited ear thickness and dermatitis index in dermatitis model compared with the dermatitis mice without treatment, showing a similar curative effect compared with daily mizolastine injection treatment, and the improvement continued for several days. Inflammatory cells infiltration into the ears and the plasma level of immunoglobulin E were also suppressed by mizolastine microparticles according to the histopathology analysis. In conclusion, the results suggested that drug-loaded microparticles could be a proper candidate for the treatment of skin diseases.
    Journal of Microencapsulation 12/2014; 32(2):1-9. DOI:10.3109/02652048.2014.995727
  • [Show abstract] [Hide abstract]
    ABSTRACT: Micronisation of simvastatin dissolved in acetone, dimethyl sulfoxide and ethanol with supercritical carbon dioxide as antisolvent was successfully performed using a supercritical antisolvent technique. The effect of a few process parameters such as precipitation temperature, the pressure and solute concentration in the liquid solution has been studied to evaluate their influence on morphology and size of particles. The micronised simvastatin were evaluated for drug content, particle size analysis and in vitro dissolution profiles. Fourier transform infrared spectroscopy, differential scanning calorimetry and PXRD patterns was used to study the possible changes after micronisation of simvastatin. The dissolution rate was increased after micronised compared with pure simvastatin in distilled water, pH 1.2 buffer and pH 7.0 buffer. In vivo performance of the optimised formulation was evaluated in rats using pharmacodynamic marker parameters like serum total cholesterol (CH) and triglycerides (TG) for 21 days. Pharmacodynamic studies of micronised simvastatin revealed improved reduction in CH and TG values as compared with pure simvastatin indicating improved bioavailability. In vivo pharmacokinetics in rats showed an increase in bioavailability of micronised simvastatin (3.14 times) compared with plain simvastatin.
    Journal of Microencapsulation 12/2014; 32(2). DOI:10.3109/02652048.2014.995726
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To develop a novel preparation approach of solid Self-Emulsifying Drug Delivery System (s-SEDDS) based on spray congealing as potential drug delivery technology for poorly water-soluble drug Glibenclamide (GBD). Methods: Several systems were formulated using suitable excipients, solid at room temperature, with different hydrophilic-lipophilic balance, such as Myverol, Myvatex, Gelucire®50/13 and Gelucire®44/14. Cremophor®EL and Poloxamer 188 were selected as surfactants and PEG 4000 as co-solvent. Results: The screening of the best carrier for s-SEDDS manufacturing revealed that Gelucire®50/13 had greater performance. Then, surfactant-co-solvent systems were developed. Dissolution studies showed that all the formulations promoted the solubilisation performance of the GBD with respect to pure drug; in particular the formulation containing Gelucire®50/13 and PEG 4000 increased the drug solubilisation of five times. These microparticles showed self-dispersibility within 60 min and micelles dimensions around 360 nm. Conclusions: Spray congealing is a promising novel manufacturing technique of solid self-emulsifying systems.
    Journal of Microencapsulation 11/2014; 32(2):1-12. DOI:10.3109/02652048.2014.985341